New research comparing HIV medications set to change international recommendations
The WHO-funded study shows that dolutegravir is the optimal choice for first-line treatment of HIV
Learn MoreAugust 24, 2020
Examining the results of CTN 297: Black PRAISE
The Black PRAISE team have pioneered a novel intervention aimed at reducing HIV-related stigma while strengthening the HIV knowledge base among Black church congregations in Ontario
Learn More
Engage-COVID-19
New funding for CTN 300-2 will allow the study team to document COVID-19 infection, immunity, and related determinants in gay, bisexual, and other men who have sex with men
Learn More
OPAL-COVID-19 Study
Dr. Bertrand Lebouché joins the creators of the health app Opal to repurpose it for COVID-19 patients recovering from home
Learn More
A collaborative approach to women-centred HIV care
The CTN 262 CHIWOS study have launched an all-encompassing Women-Centred HIV Care model and two toolkits
Learn More
The CTN and COVID-19
At the CTN, we are proud to be a conduit for the rapid implementation of national co-ordinated COVID-19 trials
Learn More
Here’s what we know about COVID-19 & HIV
Many questions remain about COVID-19 and what it means for people living with HIV. We explore the research so far
Learn More
Drug repurposing: could an HIV medication help in the fight against COVID-19?
Dr. Darrell Tan received funding for his study ‘COVID-19 ring-based prevention trial for undermining spread (CORPUS)’
Learn More
The enigma of HIV’s effects on aging
People living with HIV present with age-related diseases sooner than the general population, but little is known as to why
Learn More